Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7744850 | 0.84 | OPRM1 (0.56) | OPRM1HDAC1 | |
| SCHEMBL5641709 | 0.84 | OPRM1 (0.52) | OPRM1MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL11467518 | 0.83 | OPRM1 (0.46) | OPRM1ALDH1A1SMN1; SMN2 | |
| SCHEMBL15548256 | 0.83 | KDM4E (0.46) | OPRM1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL11462401 | 0.82 | LMNA (0.48) | OPRM1LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL14790321 | 0.82 | OPRM1 (0.42) | OPRM1LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL14710596 | 0.82 | OPRM1 (0.42) | OPRM1LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL1163278 | 0.80 | OPRM1 (0.37) | OPRM1LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL14710667 | 0.78 | OPRM1 (0.40) | OPRM1LMNAMEN1KMT2AL3MBTL1 | |
| SCHEMBL8584110 | 0.77 | ALDH1A1 (0.51) | LMNAMEN1KMT2AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-17 | — | — | US | disclosed |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | OPRM1 1387/4885LMNA 701/4885MEN1 1384/4885 |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | OPRM1 1387/4885LMNA 701/4885MEN1 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.